Literature DB >> 24683263

Effects of photodynamic therapy with verteporfin for the treatment of chronic central serous chorioretinopathy: An uncontrolled, open-label, observational study.

Yildirim Bayezit Sakalar1, Ugur Keklikci1, Kaan Unlu1, Mehmet Fuat Alakus1, Ismail Hamdi Kara2.   

Abstract

BACKGROUND: Central serous chorioretinopathy is an idiopathic disorder that leads to serous neurosensory retinal detachment. The disorder is usually self-limited and resolves spontaneously; however, sometimes neurosensory retinal detachment persists. This form of the disorder is called chronic central serous chorioretinopathy (CCSC).
OBJECTIVE: The aim of this study was to assess the effects of photodynamic therapy (PDT) on visual acuity with full-dose verteporfin for CCSC.
METHODS: The eyes of patients with CCSC were included in the study. Ophthalmic examination including best-corrected visual acuity (BCVA), fundus examination, fluorescein angiography, and optical coherence tomography was performed before treatment and at 1, 3, 6, 9, and 12 months. PDT with full-dose verteporfin (6 μ/m(2) of body surface area) was applied only to areas of active leakage. BCVA was converted to a log of the minimum angle of resolution (logMAR) equivalent for statistical analysis. Central foveal thickness and BCVA between baseline and follow-up were compared.
RESULTS: Seventeen eyes of 16 patients (13 males, 3 females; mean [SD] age, 39.75 [7.51] years; mean duration of follow-up, 13.06 [1.82] months) were used in the study. The mean (SEM) logMAR BCVA was 0.26 (0.07) at baseline and 0.04 (0.02) at 12 months. Mean logMAR BCVA values at baseline (0.259) and after treatment (0.112, 0.053, 0.047, 0.041, and 0.041 at 1, 3, 6, 9, and 12 months, respectively) differed significantly (P = 0.006, P = 0.005, P = 0.005, P = 0.005, and P = 0.005). There was a significant difference in the mean central foveal thickness at the final visit (169 μm) compared with the baseline value (383 μm; P < 0.001). BCVA decreased in one eye (20/20 vs 20/25) and persisted during follow-up; in the other 16 eyes, BCVA either increased (n = 10) or remained stable (n = 6).
CONCLUSIONS: In this small, open-label study, patients with CCSC treated with a single course of PDT with full-dose verteporfin had significant improvement from baseline in BCVA and resolution of subretinal fluid accumulation and active leakage. Treatment was generally well tolerated, but one patient had worsening in BCVA.

Entities:  

Keywords:  central serous chorioretinopathy; optical coherence tomography; photodynamic therapy; verteporfin

Year:  2010        PMID: 24683263      PMCID: PMC3967338          DOI: 10.1016/j.curtheres.2010.04.002

Source DB:  PubMed          Journal:  Curr Ther Res Clin Exp        ISSN: 0011-393X


  27 in total

Review 1.  Expanded hypothesis on the mechanism of photodynamic therapy action on choroidal neovascularization.

Authors:  R W Flower
Journal:  Retina       Date:  1999       Impact factor: 4.256

Review 2.  Idiopathic central serous chorioretinopathy.

Authors:  D Hussain; J D Gass
Journal:  Indian J Ophthalmol       Date:  1998-09       Impact factor: 1.848

3.  Histopathological changes following photodynamic therapy in human eyes.

Authors:  Ursula Schmidt-Erfurth; Horst Laqua; Ursula Schlötzer-Schrehard; Arne Viestenz; Gottfried O H Naumann
Journal:  Arch Ophthalmol       Date:  2002-06

4.  Theoretical investigation of the role of choriocapillaris blood flow in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration.

Authors:  R W Flower; C von Kerczek; L Zhu; A Ernest; C Eggleton; L D Topoleski
Journal:  Am J Ophthalmol       Date:  2001-07       Impact factor: 5.258

5.  Type A behavior and central serous chorioretinopathy.

Authors:  L A Yannuzzi
Journal:  Trans Am Ophthalmol Soc       Date:  1986

6.  Pathogenesis of disciform detachment of the neuroepithelium.

Authors:  J D Gass
Journal:  Am J Ophthalmol       Date:  1967-03       Impact factor: 5.258

7.  Retinal atrophy in idiopathic central serous chorioretinopathy.

Authors:  Maria S M Wang; Birgit Sander; Michael Larsen
Journal:  Am J Ophthalmol       Date:  2002-06       Impact factor: 5.258

8.  Central serous chorioretinopathy in younger and older adults.

Authors:  R F Spaide; L Campeas; A Haas; L A Yannuzzi; Y L Fisher; D R Guyer; J S Slakter; J A Sorenson; D A Orlock
Journal:  Ophthalmology       Date:  1996-12       Impact factor: 12.079

9.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

10.  Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes.

Authors:  Ursula Schlötzer-Schrehardt; Arne Viestenz; Gottfried O H Naumann; Horst Laqua; S Michels; Ursula Schmidt-Erfurth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-08-27       Impact factor: 3.117

View more
  2 in total

Review 1.  Photodynamic therapy for central serous chorioretinopathy.

Authors:  O C Erikitola; R Crosby-Nwaobi; A J Lotery; S Sivaprasad
Journal:  Eye (Lond)       Date:  2014-06-20       Impact factor: 3.775

Review 2.  Current Therapeutic Approaches to Chronic Central Serous Chorioretinopathy

Authors:  Samet Gülkaş; Özlem Şahin
Journal:  Turk J Ophthalmol       Date:  2019-02-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.